M. Pike, M. Krailo, B. Henderson, J. Casagrande, and D. Hoel, ???Hormonal??? risk factors, ???breast tissue age??? and the age-incidence of breast cancer, Nature, vol.65, issue.5920, pp.767-770, 1983.
DOI : 10.1038/303767a0

W. Mc-guire, Hormone receptor: their role in predicting prognosis and response to endocrine therapy, Semi Oncol, vol.5, pp.2428-2433, 1978.

B. Fisher, J. Jeong, and J. Dignam, Findings From Recent National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies in Stage I Breast Cancer, JNCI Monographs, vol.2001, issue.30, pp.62-66, 2001.
DOI : 10.1093/oxfordjournals.jncimonographs.a003463

I. Henderson, Risk factors for breast cancer development, Cancer, vol.32, issue.S6, pp.2127-2140, 1993.
DOI : 10.1002/1097-0142(19930315)71:6+<2127::AID-CNCR2820711602>3.0.CO;2-2

K. Korach, Insights from the study of animals lacking functional estrogen receptor, Science, vol.266, issue.5190, pp.1524-1527, 1994.
DOI : 10.1126/science.7985022

J. Gustafsson, Estrogen receptor beta--a new dimension in estrogen mechanism of action, Journal of Endocrinology, vol.163, issue.3, pp.379-383, 1999.
DOI : 10.1677/joe.0.1630379

S. Dupont, A. Krust, A. Gansmuller, A. Dierich, P. Chambon et al., Effect of single and compound knockouts of estrogen receptors (ER ) and ß (ERß) on mouse reproductive phenotypes, Development, vol.127, pp.4277-4291, 2000.

V. Kumar, S. Green, G. Stack, M. Berry, J. Jin et al., Functional domains of the human estrogen receptor, Cell, vol.51, issue.6, pp.941-951, 1987.
DOI : 10.1016/0092-8674(87)90581-2

N. Mckenna, R. Lanz, O. Malley, and B. , Nuclear Receptor Coregulators: Cellular and Molecular Biology, Endocrine Reviews, vol.20, issue.3, pp.321-344, 1999.
DOI : 10.1210/er.20.3.321

A. Shiau, D. Barstad, and P. Loria, The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen, Cell, vol.95, issue.7, pp.927-964, 1998.
DOI : 10.1016/S0092-8674(00)81717-1

A. Brzozowski, A. Pike, and Z. Dauter, Molecular basis of agonism and antagonism in the oestrogen receptor, Nature, vol.389, issue.6652, pp.753-758, 1997.
DOI : 10.1038/39645

D. Moras and H. Gronemeyer, The nuclear receptor ligand-binding domain: structure and function, Current Opinion in Cell Biology, vol.10, issue.3, pp.384-91, 1998.
DOI : 10.1016/S0955-0674(98)80015-X

B. Katzenellenbogen, J. Katzenellenbogen, and . Biomedicine, BIOMEDICINE: Enhanced: Defining the "S" in SERMs, Science, vol.295, issue.5564, pp.2380-2381, 2002.
DOI : 10.1126/science.1070442

D. Mcdonnell, C. Connor, A. Wijayaratne, C. Chang, and J. Norris, Definition of the Molecular and Cellular Mechanisms Underlying the Tissue-selective Agonist/Antagonist Activities of Selective Estrogen Receptor Modulators, Recent Progress in Hormone Research, vol.57, issue.1, pp.295-316, 2002.
DOI : 10.1210/rp.57.1.295

J. Macgregor and V. Jordan, Basic guide to the mechanisms of antiestrogen action, Pharmacol Rev, vol.50, pp.151-96, 1998.

S. Kato, H. Endoh, and Y. Masuhiro, Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase, Science, vol.270, issue.5241, pp.1491-1494, 1995.
DOI : 10.1126/science.270.5241.1491

G. Bunone, P. Briand, R. Miksicek, and D. Picard, Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation, EMBO J, vol.15, pp.2174-2183, 1996.

M. Gaub, M. Bellard, I. Scheuer, P. Chambon, and P. Sassone-corsi, Activation of the ovalbumin gene by the estrogen receptor involves the Fos-Jun complex, Cell, vol.63, issue.6, pp.1267-1276, 1990.
DOI : 10.1016/0092-8674(90)90422-B

K. Paech, P. Webb, and G. Kuiper, Differential Ligand Activation of Estrogen Receptors ER and ER at AP1 Sites, Science, vol.277, issue.5331, pp.1508-1510, 1997.
DOI : 10.1126/science.277.5331.1508

C. Teyssier, K. Belguise, F. Galtier, and D. Chalbos, Characterization of the Physical Interaction between Estrogen Receptor ?? and JUN Proteins, Journal of Biological Chemistry, vol.276, issue.39, pp.36361-36369, 2001.
DOI : 10.1074/jbc.M101806200

A. Ray, K. Prefontaine, and P. Ray, Down-modulation of interleukin-6 gene expression by 17??estradiol in the absence of high affinity DNA binding by the estrogen receptor, J Biol Chem, vol.269, pp.12940-12946, 1994.

B. Stein and M. Yang, Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-?B and C, EBP??? Mol Cell Endocrinol, vol.15, pp.4971-4979, 1995.

S. Batistuzzo-de-medeiros, G. Krey, A. Hihi, and W. Wahli, Functional interactions between the estrogen receptor and the transcription activator Sp1 regulate the estrogen-dependent transcriptional activity of the vitellogenin A1 promoter, J Biol Chem, vol.29, pp.18250-18260, 1997.

W. Porter, B. Saville, D. Hoivik, and S. Safe, Functional Synergy between the Transcription Factor Sp1 and the Estrogen Receptor, Molecular Endocrinology, vol.11, issue.11, pp.1569-1580, 1997.
DOI : 10.1210/mend.11.11.9916

R. Pietras and C. Szego, Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells, Nature, vol.32, issue.5589, pp.69-72, 1977.
DOI : 10.1038/265069a0

T. Simoncini, A. Hafezi-moghadam, D. Brazil, K. Ley, W. Chin et al., Interaction of estrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase, Nature, vol.407, pp.538-541, 2000.

S. Kousteni, T. Bellido, and L. Plotkin, Nongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors Dissociation from Transcriptional Activity, Cell, vol.104, issue.5, pp.719-730, 2001.
DOI : 10.1016/S0092-8674(02)08100-X

S. Cowley and M. Parker, A comparison of transcriptional activation by ER?? and ER??, The Journal of Steroid Biochemistry and Molecular Biology, vol.69, issue.1-6, pp.165-175, 1999.
DOI : 10.1016/S0960-0760(99)00055-2

K. Pettersson, F. Delaunay, and J. Gustafsson, Estrogen receptor beta acts as a dominant regulator of estrogen signaling, Oncogene, vol.43, pp.4970-4978, 2000.

S. Saji, E. Jensen, S. Nilsson, T. Rylander, M. Warner et al., Estrogen receptors alpha and beta in the rodent mammary gland, Proceedings of the National Academy of Sciences, vol.42, issue.13, pp.337-342, 2000.
DOI : 10.1021/jm990101b

R. Clarke, A. Howell, C. Potten, and E. Anderson, Dissociation between steroid receptor expression and cell proliferation in the human breast, Cancer Res, vol.57, pp.4987-4991, 1997.

U. Meinhardt and P. Mullis, The Essential Role of the Aromatase/P450arom, Seminars in Reproductive Medicine, vol.20, issue.3, pp.277-84, 2002.
DOI : 10.1055/s-2002-35374

S. Khan, M. Rogers, K. Khurana, M. Meguid, and P. Numann, Estrogen Receptor Expression in Benign Breast Epithelium and Breast Cancer Risk, JNCI Journal of the National Cancer Institute, vol.90, issue.1, pp.37-42, 1998.
DOI : 10.1093/jnci/90.1.37

P. Roger, J. Daures, and T. Maudelonde, Dissociated overexpression of cathepsin Dand estrogen receptor alpha in preinvasive mammary tumors, Human Pathology, vol.31, issue.5, pp.593-600, 2000.
DOI : 10.1053/hp.2000.6687

B. Shoker, C. Jarvis, and R. Clarke, Estrogen Receptor-Positive Proliferating Cells in the Normal and Precancerous Breast, The American Journal of Pathology, vol.155, issue.6, pp.1811-1815, 1999.
DOI : 10.1016/S0002-9440(10)65498-3

P. Roger, E. Sahla, M. Mäkelä, S. Gustafsson, J. Baldet et al., Decreased expression of estrogen receptor ß protein in proliferative preinvasive mammary tumors, Cancer Res, vol.61, pp.2537-2578, 2001.

W. Dupont and D. Page, Risk Factors for Breast Cancer in Women with Proliferative Breast Disease, New England Journal of Medicine, vol.312, issue.3, pp.146-151, 1985.
DOI : 10.1056/NEJM198501173120303

L. Hilakivi-clarke, Estrogens, BRCA1, and breast cancer, Cancer Res, vol.60, pp.4993-5001, 2000.

O. Connell, P. Pekkel, V. Fuqua, S. Osborne, C. Clark et al., Analysis of Loss of Heterozygosity in 399 Premalignant Breast Lesions at 15 Genetic Loci, JNCI Journal of the National Cancer Institute, vol.90, issue.9, pp.697-703, 1998.
DOI : 10.1093/jnci/90.9.697

C. Osborne, Steroid hormone receptors in breast cancer management, Breast Cancer Research and Treatment, vol.269, issue.Suppl, pp.227-265, 1998.
DOI : 10.1023/A:1006132427948

V. Bardou, G. Arpino, R. Elledge, C. Osborne, and G. Clark, Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases, Journal of Clinical Oncology, vol.21, issue.10
DOI : 10.1200/JCO.2003.09.099

K. Zhu, L. Bernard, R. Levine, and S. Williams, Estrogen receptor status of breast cancer: a marker of different stages of tumor or different entities of the disease?, Medical Hypotheses, vol.49, issue.1, pp.69-75, 1997.
DOI : 10.1016/S0306-9877(97)90255-3

M. Sheikh, M. Garcia, P. Pujol, J. Fontana, and H. Rochefort, Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers?, Invasion Metastasis, vol.14, pp.329-365, 1994.

E. Thompson, S. Paik, and N. Brünner, Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines, Journal of Cellular Physiology, vol.46, issue.4, pp.534-544, 1992.
DOI : 10.1002/jcp.1041500314

M. Garcia, D. Derocq, G. Freiss, and H. Rochefort, Activation of estrogen receptor into a receptornegative breast cancer cell line decreases the metastatic and invasive potential of the cells, Proc Natl Acad Sci, vol.89, pp.1538-11542, 1992.

S. Jiang and V. Jordan, Growth Regulation of Estrogen Receptor-Negative Breast Cancer Cells Transfected With Complementary DNAs for Estrogen Receptor, JNCI Journal of the National Cancer Institute, vol.84, issue.8, pp.580-591, 1992.
DOI : 10.1093/jnci/84.8.580

A. Taylor and F. Al-azzawi, Immunolocalisation of oestrogen receptor beta in human tissues, Journal of Molecular Endocrinology, vol.24, issue.1, pp.145-155, 2000.
DOI : 10.1677/jme.0.0240145

T. Jarvinen, M. Pelto-huikko, K. Holli, and J. Isola, Estrogen Receptor ?? Is Coexpressed with ER?? and PR and Associated with Nodal Status, Grade, and Proliferation Rate in Breast Cancer, The American Journal of Pathology, vol.156, issue.1, pp.29-35, 2000.
DOI : 10.1016/S0002-9440(10)64702-5

C. Palmieri, G. Cheng, and S. Saji, Estrogen receptor beta in breast cancer, Endocrine Related Cancer, vol.9, issue.1, pp.1-13, 2002.
DOI : 10.1677/erc.0.0090001

S. Hayashi, H. Eguchi, and K. Tanimoto, The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application, Endocrine Related Cancer, vol.10, issue.2, pp.193-202, 2003.
DOI : 10.1677/erc.0.0100193

S. Fuqua, R. Schiff, and I. Parra, Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters, Cancer Res, vol.63, pp.2434-2439, 2003.

S. Fuqua and D. Wolf, Molecular aspects of estrogen receptor variants in breast cancer, Breast Cancer Research and Treatment, vol.53, issue.3, pp.233-241, 1995.
DOI : 10.1007/BF00665974

L. Murphy, E. Leygue, H. Dotzlaw, D. Douglas, A. Coutts et al., Oestrogen Receptor Variants and Mutations in Human Breast Cancer, Annals of Medicine, vol.93, issue.3, pp.221-234, 1997.
DOI : 10.1016/0092-8674(90)90343-D

A. Huang, E. Leygue, L. Snell, L. Murphy, and P. Watson, Expression of estrogen receptor variant messenger RNAs and determination of estrogen receptor status in human breast cancer, Am J Pathol, vol.150, pp.1827-1833, 1997.

I. Erenburg, B. Schachter, M. Y. Lopez, R. Ossowski, and L. , Loss of an estrogen receptor isoform (ER alpha delta 3) in breast cancer and the consequences of its reexpression: interference with estrogen-stimulated properties of malignant transformation, Mol Endocrinol, vol.11, pp.2004-2015, 1997.

A. Desai, Y. Luqmai, and J. Walters, Presence of exon 5-deleted oestrogen receptor in human breast cancer: functional analysis and clinical significance, British Journal of Cancer, vol.75, issue.8, pp.1173-1184, 1997.
DOI : 10.1038/bjc.1997.202

W. Park, J. Choi, E. Hwang, and J. Lee, Identification of a variant estrogen receptor lacking exon 4 and its coexpression with wild-type estrogen receptor in ovarian carcinomas, Clin Cancer Res, vol.2, pp.2029-2035, 1996.

S. Ogawa, S. Inoue, and T. Watanabe, Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human, Nucleic Acids Research, vol.26, issue.15, pp.3505-3512, 1998.
DOI : 10.1093/nar/26.15.3505

S. Saji, Y. Omoto, and C. Shimizu, Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor, Cancer Res, vol.62, pp.4849-53, 2002.

I. Poola, J. Abraham, and A. Liu, Estrogen receptor beta splice variant mRNAs are differentially altered during breast carcinogenesis, The Journal of Steroid Biochemistry and Molecular Biology, vol.82, issue.2-3, pp.169-79, 2002.
DOI : 10.1016/S0960-0760(02)00185-1

. Omotoy, H. Eguchi, Y. Yamamoto-yamaguchi, and S. Hayashi, Estrogen receptor (ER) ??1 and ER??cx/??2 inhibit ER?? function differently in breast cancer cell line MCF7, Oncogene, vol.22, issue.32, pp.5011-5020, 2003.
DOI : 10.1038/sj.onc.1206787

G. Beatson, On the treatment of inoperable cancer of the mamma: suggestion for a new method of treatment with illustrative cases, Lancet, vol.ii, pp.104-107, 1896.

A. Lacassagne, Hormonal Pathogenesis of Adenocarcinoma of the Breast, The American Journal of Cancer, vol.27, issue.2, pp.217-225, 1936.
DOI : 10.1158/ajc.1936.217

S. Doisneau-sixou, C. Sergio, J. Carroll, R. Hui, E. Musgrove et al., Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells, Endocrine Related Cancer, vol.10, issue.2, pp.179-186, 2003.
DOI : 10.1677/erc.0.0100179

R. Dickson and M. Lippman, Growth Factors in Breast Cancer, Endocrine Reviews, vol.16, issue.5, pp.559-589, 1995.
DOI : 10.1210/edrv-16-5-559

M. Berry, D. Metzger, and P. Chambon, Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4- hydroxytamoxifen, EMBO J, vol.9, pp.2811-2819, 1990.

O. Prall, E. Rogan, and R. Sutherland, Estrogen regulation of cell cycle progression in breast cancer cells, The Journal of Steroid Biochemistry and Molecular Biology, vol.65, issue.1-6, pp.169-174, 1998.
DOI : 10.1016/S0960-0760(98)00021-1

S. Caristi, J. Galera, and F. Matarese, Estrogens do not modify MAP kinase-dependent nuclear signaling during stimulation of early G(1) progression in human breast cancer cells, Cancer Res, vol.61, pp.6360-6366, 2001.

M. Pegram and D. Slamon, Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer : evidence for receptor-enhanced chemosensitivity, Seminars Oncol, vol.26, pp.89-95, 1999.

H. Rochefort, E. Liaudet, and M. Garcia, Alterations and role of human cathepsin D in cancer metastasis, Enzyme Protein, vol.49, pp.106-122, 1996.

M. Mareel and A. Leroy, Clinical, Cellular, and Molecular Aspects of Cancer Invasion, Physiological Reviews, vol.83, issue.2, pp.337-76, 2003.
DOI : 10.1152/physrev.00024.2002

O. Blaschuk, S. Munro, and R. Farookhi, E-cadherin, estrogens and cancer: is there a connection ?, Can J Oncol, vol.4, pp.291-301, 1994.

S. Oesterreich, W. Deng, and S. Jiang, Estrogen-mediated down-regulation of E-cadherin in breast cancer cells, Cancer Res, vol.63, pp.5203-5208, 2003.

S. Gruvberger, M. Ringner, and Y. Chen, Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns, Cancer Res, vol.61, pp.5979-84, 2001.

J. Marsden and N. Backs, Hormone replacement therapy and breast cancer, Endocrine Related Cancer, vol.3, issue.2, pp.81-97, 1996.
DOI : 10.1677/erc.0.0030081

C. Li, K. Malone, N. Weiss, and J. Daling, Tamoxifen Therapy for Primary Breast Cancer and Risk of Contralateral Breast Cancer, JNCI Journal of the National Cancer Institute, vol.93, issue.13, pp.1008-1013, 2001.
DOI : 10.1093/jnci/93.13.1008

N. Platet, C. Prevostel, D. Derocq, D. Joubert, H. Rochefort et al., Breast cancer cell invasiveness: Correlation with protein kinase C activity and differential regulation by phorbol ester in estrogen receptor-positive and -negative cells, International Journal of Cancer, vol.95, issue.5, pp.750-756, 1998.
DOI : 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A

J. Price, A. Polyzos, R. Zhang, and L. Daniels, Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice, Cancer Res, vol.50, pp.717-721, 1990.

A. Albini, J. Graf, and G. Kitten, 17 beta-estradiol regulates and v-Ha-ras transfection constitutively enhances MCF7 breast cancer cell interactions with basement membrane., Proceedings of the National Academy of Sciences, vol.83, issue.21, pp.8182-8186, 1986.
DOI : 10.1073/pnas.83.21.8182
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC386891

E. Thompson, R. Reich, and T. Shima, Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens, Cancer Res, vol.48, pp.6764-6768, 1998.

H. Rochefort, N. Platet, and Y. Hayashido, Estrogen receptor mediated inhibition of cancer cell invasion and motility: An overview, The Journal of Steroid Biochemistry and Molecular Biology, vol.65, issue.1-6, pp.163-168, 1998.
DOI : 10.1016/S0960-0760(98)00010-7

M. Garcia, D. Derocq, and N. Platet, Both estradiol and tamoxifen decrease proliferation and invasiveness of cancer cells transfected with a mutated estrogen receptor, The Journal of Steroid Biochemistry and Molecular Biology, vol.61, issue.1-2, pp.11-17, 1997.
DOI : 10.1016/S0960-0760(96)00255-5

Y. Hayashido, A. Lucas, C. Rougeot, S. Godyna, and W. Argraves, Estradiol and fibulin-1 inhibit motility of human ovarian- and breast-cancer cells induced by fibronectin, International Journal of Cancer, vol.118, issue.4, pp.654-658, 1998.
DOI : 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7

F. Kolodgie, A. Jacob, and P. Wilson, Estradiol attenuates directed migration of vascular smooth muscle cells in vitro, Am J Pathol, vol.148, pp.969-976, 1996.

B. Long and D. Rose, Invasive capacity and regulation of urokinase-type plasminogen activator in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells, and a transfectant (S30) stably expressing ER, Cancer Letters, vol.99, issue.2, pp.209-215, 1996.
DOI : 10.1016/0304-3835(95)04066-8

N. Platet and M. Garcia, A New Bioassay Using Transient Transfection for Invasion-Related Gene Analysis, Invasion and Metastasis, vol.18, issue.4, pp.198-206, 1999.
DOI : 10.1159/000024513

N. Platet, S. Cunat, D. Chalbos, H. Rochefort, and M. Garcia, Unliganded and Liganded Estrogen Receptors Protect against Cancer Invasion via Different Mechanisms, Molecular Endocrinology, vol.14, issue.7, pp.999-1009, 2000.
DOI : 10.1210/mend.14.7.0492

M. Garcia and H. Rochefort, Estrogen receptor targeted therapies of breast cancer, Cur Opin Oncol Endocr Metab Invest Drugs, vol.2, pp.60-67, 2000.

I. Laios, F. Journe, G. Laurent, D. Nonclercq, R. Toillon et al., Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens, The Journal of Steroid Biochemistry and Molecular Biology, vol.87, issue.2-3, pp.207-221, 2003.
DOI : 10.1016/j.jsbmb.2003.09.011

M. Bracke, C. Charlier, E. Bruyneel, C. Labit, M. Mareel et al., Tamoxifen restores the E-cadherin function in human breast cancer MCF-7/6 cells and suppresses their invasive phenotype, Cancer Res, vol.54, pp.4607-4609, 1994.

S. Green, V. Kumar, I. Theulaz, W. Wahli, and P. Chambon, The N-terminal DNA-binding 'zinc finger' of the oestrogen and glucocorticoid receptors determines target gene specificity, EMBO J, vol.7, pp.3037-3081, 1988.

N. Roodi, L. Bailey, and W. Kao, Estrogen Receptor Gene Analysis in Estrogen Receptor-Positive and Receptor-Negative Primary Breast Cancer, JNCI Journal of the National Cancer Institute, vol.87, issue.6, pp.446-451, 1995.
DOI : 10.1093/jnci/87.6.446

Q. Zhang, A. Borg, D. Wolf, S. Oesterreich, and S. Fuqua, An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer, Cancer Res, vol.57, pp.1244-1249, 1997.

S. Fuqua, C. Wiltschke, and Q. Zhang, A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions, Cancer Res, vol.60, pp.4026-4029, 2000.

S. Come, A. Buzdar, and C. Arteaga, Second international conference on recent advances and future directions in endocrine manipulation of breast cancer: summary consensus statement, Clin Cancer Res, vol.9, pp.443-446, 2003.

V. Jordan and C. Murphy, Endocrine Pharmacology of Antiestrogens as Antitumor Agents*, Endocrine Reviews, vol.11, issue.4, pp.578-610, 1990.
DOI : 10.1210/edrv-11-4-578

B. Fisher, S. Anderson, and E. Tan-chiu, Tamoxifen and chemotherapy for axillary nodenegative , estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23, J Clin Oncol, vol.4, pp.931-942, 2001.

G. Schwartz, The Current Treatment of Ductal Carcinoma in Situ, The Breast Journal, vol.7, issue.5, pp.308-318, 2001.
DOI : 10.1054/brst.1999.0156

A. Wakeling and J. Bowler, ICI 182,780, a new antioestrogen with clinical potential, The Journal of Steroid Biochemistry and Molecular Biology, vol.43, issue.1-3, pp.173-177, 1992.
DOI : 10.1016/0960-0760(92)90204-V

J. Robertson, C. Osborne, and A. Howell, Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women, Cancer, vol.17, issue.2, pp.229-238, 2003.
DOI : 10.1002/cncr.11468

J. Rossouw, G. Anderson, and R. Prentice, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial, JAMA, vol.288, pp.321-333, 2002.

H. Mouridsen, M. Gershanovich, and Y. Sun, Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group, Journal of Clinical Oncology, vol.19, issue.10, pp.2596-2606, 2001.
DOI : 10.1200/JCO.2001.19.10.2596

R. Santen, Inhibition of aromatase: insights from recent studies, Steroids, vol.68, issue.7-8, pp.559-567, 2003.
DOI : 10.1016/S0039-128X(03)00096-5

M. Ellis, A. Coop, and B. Singh, Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1??? and/or ErbB-2???Positive, Estrogen Receptor???Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial, Journal of Clinical Oncology, vol.19, issue.18, pp.3808-3816, 2001.
DOI : 10.1200/JCO.2001.19.18.3808

R. Coleman, Should bisphosphonates be the treatment of choice for metastatic bone disease?, Seminars in Oncology, vol.28, pp.35-41, 2001.
DOI : 10.1016/S0093-7754(01)90230-1

H. Rochefort and M. Garcia, The estrogenic and antiestrogenic activities of androgens in female target tissues, Pharmacology & Therapeutics, vol.23, issue.2, pp.193-216, 1983.
DOI : 10.1016/0163-7258(83)90013-X

J. Adams, M. Garcia, and H. Rochefort, Estrogenic effects of physiological concentrations of 5- androstene-3 beta, 17 beta-diol and its metabolism in MCF7 human breast cancer cells, Cancer Res, vol.41, pp.4720-4726, 1981.

C. Osborne, J. Pippen, and S. Jones, Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial, Journal of Clinical Oncology, vol.20, issue.16, pp.3386-3395, 2002.
DOI : 10.1200/JCO.2002.10.058

M. Gutman, S. Couillard, F. Labrie, B. Candas, and C. Labrie, Effect of treatment sequence with radiotherapy and the antiestrogen EM 800 on the growth of ZR 75 1 human mammary carcinoma in nude mice, International Journal of Cancer, vol.353, issue.2, pp.268-276, 2003.
DOI : 10.1002/ijc.10803

B. Fisher, J. Costantino, and D. Wickerham, Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, JNCI Journal of the National Cancer Institute, vol.90, issue.18, pp.1371-1388, 1998.
DOI : 10.1093/jnci/90.18.1371

W. Park and V. Jordan, Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention, Trends in Molecular Medicine, vol.8, issue.2, pp.82-88, 2002.
DOI : 10.1016/S1471-4914(02)02282-7

J. Cauley, L. Norton, and M. Lippman, Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial, Breast Cancer Research and Treatment, vol.280, issue.2, pp.125-134, 2001.
DOI : 10.1023/A:1006478317173

V. Vogel, J. Costantino, D. Wickerham, W. Cronin, and N. Wolmark, The Study of Tamoxifen and Raloxifene: Preliminary Enrollment Data from a Randomized Breast Cancer Risk Reduction Trial, Clinical Breast Cancer, vol.3, issue.2, pp.153-159, 2002.
DOI : 10.3816/CBC.2002.n.020

D. Losordo and J. Isner, Estrogen and Angiogenesis : A Review, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.21, issue.1, pp.6-12, 2001.
DOI : 10.1161/01.ATV.21.1.6

L. Castagnetta, O. Granata, and A. Traina, A Role for Sex Steroids in Autoimmune Diseases, Annals of the New York Academy of Sciences, vol.876, issue.S1A, pp.193-203, 2002.
DOI : 10.1111/j.1749-6632.2002.tb04215.x

A. Cathiard and P. D. , is a Study Engineer at the National Institute for Health and Medical Research (INSERM), Laboratory of Molecular and Cellular Endocrinology of Cancers, She has had a long-standing involvement in research on steroid hormone action and endocrinology, 1981.

. Gleizes, Michel Gleizes is a laboratory technician at the University of Montpellier, France, with experience in immunohistochemistry, protein biochemistry and cell biology